Decreased RAGE expression in peripheral blood mononuclear cells of patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 27, Issue 3, 2009, Pages 483-490

  Drinda, Stefan ^a   Franke, Sybille ^a   Eidner, Thorsten ^a   Schmidt, Carsten ^a   Rüster, Christiane ^a   Bondeva, Tzvetanka ^a   Hein, Gert ^a   Wolf, Gunter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Crohn's disease; Peripheral blood mononuclear cells; RAGE expression; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AZATHIOPRINE; CALGRANULIN; CD11B ANTIGEN; COMPLETE ADVANCED GLYCATION END PRODUCT RECEPTOR; ENDOGENOUS SECRETORY ADVANCED GLYCATION END PRODUCT RECEPTOR; ETANERCEPT; INFLIXIMAB; ISOPROTEIN; LEFLUNOMIDE; MESSENGER RNA; METHOTREXATE; N TRUNCATED ADVANCED GLYCATION END PRODUCT RECEPTOR; PREDNISOLONE; PROTEIN S 100; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN VARIANT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CROHN DISEASE; DOWN-REGULATION; FEMALE; HUMANS; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; YOUNG ADULT;

EID: 67651149868     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. MUELLER RB, SKAPENKO A, WENDLER J et al.: class II expression on myeloid cells inversely correlates with disease progression in early rheumatoid arthritis. Rheumatology 2007; 46: 931-933
2. SCHMIDT AM, YAN SD, YAN SF et al.: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498: 99-111.
3. MOSER B, HUDSON BI, SCHMIDT AM: Soluble RAGE: a hot new biomarker for the hot joint? Arthritis Res Ther 2005; 7: 142-144
4. DONATO R: RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 2007; 7: 711-724
5. PULLERITS R, BRISSLERT M, JONSSON IM et al.: Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 2006; 54: 3898-3907
6. SCHMIDT AM, YAN SD, YAN SF et al.: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955
7. STEENVOORDEN MM, TOES RE, RONDAY HK et al.: RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro. Clin Exp Rheumatol 2007; 25: 740-742
8. YONEKURA H, YAMAMOTO Y, SAKURAI S et al.: Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370 (Pt 3): 1097-1109
9. BIERHAUS A, HUMPERT PM, MORCOS M et al.: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-886 (Pubitemid 41598688)
10. BOHLENDER JM, FRANKE S, STEIN G et al.: Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289: F645-59.
11. HUMPERT PM, DJURIC Z, KOPF S et al.: A.Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6: 9.
12. MIYATA T, ISHIGURO N, YASUDA Y et al.: Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 1998; 244: 49-59
13. HEIN GE, KÖHLER M, OELZNER P et al.: The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol Int 2005; 26: 137-141
14. TANIGUCHI N, KAWAHARA K, YONE K et al.: High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003; 48: 971-981
15. FOELL D, KANE D, BRESNIHAN B et al.: Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology 2003; 42: 1383-1389
16. SUNAHORI K, YAMAMURA M, YAMANA J et al.: Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2006; 54: 97-104.
17. EDWARDS CJ, FELDMAN JL, BEECH J et al.: Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol Med 2007; 13: 40-58.
18. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324
19. PREVOO ML, VAN 'T HOF MA, KUPER HH et al.: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48
20. WELLS GA, BECKER JC, TENG J et al.: Validation of the Disease Activity Score 28 (DAS28) and EULAR response criteria based on CRP against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on ESR. Ann Rheum Dis 2008; May 19. [Epub ahead of print]
21. BEST WR, BECKTEL JM, SINGLETON JW: Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979; 77: 843-846
22. WINSHIP DH, SUMMERS RW, SINGLETON JW et al.: National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979; 77: 829-842 (Pubitemid 9257851)
23. PFAFFL MW, DEMPFLE L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30:e36.
24. LOESER RF, YAMMANI RR, CARLSON CS et al.: Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum 2005; 52: 2376-2385
25. BATLIWALLA FM, BAECHLER EC, XIAO X et al.: Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 2005; 6: 388-397 (Pubitemid 43090514)
26. PULLERITS R, BOKAREWA M, DAHLBERG L, TARKOWSKI A: Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005; 7: R817-24.
27. FOELL D, WITTKOWSKI H, ROTH J: Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007; 3: 382-390
28. ULLOA L, MESSMER D: High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006; 17: 189-201.
29. NAKAMURA K, YAMAGISHI S, ADACHI H et al.: Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007; 13: 185-189
30. BASTA G, SIRONI AM, LAZZERINI G et al.: Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006; 91: 4628-4634
31. BARTLING B, HOFMANN HS, WEIGLE B et al.: Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005; 26: 293-301.
32. KOBAYASHI S, KUBO H, SUZUKI T et al.: Endogenous secretory receptor for advanced glycation end products in non-small cell lung carcinoma. Am J Respir Crit Care Med 2001; 175:184-189